2019 04 7th International CMV Conference in Alabama

     
Sunday, April 7, 2019 - 10:00 to Thursday, April 11, 2019 - 17:00

Sharon presented our latest economic analysis report, 'Counting the Costs of CMV' outlining the economic cost of CMV in the UK. There was much interest in our findings and statistics and these were shared with other countries. 

There were delegates from 16 different countries: USA, UK, Italy, Brazil, Canada, Sweden, China, Croatia, Belgium, France, South Africa, Australia, Japan, Germany, the Netherlands and Israel. So good to hear the interest and progress being made around the world.

Many talks centred on prevention and treatment, with presentations on vaccines from 4 pharmaceuticals - Merck, Moderna, City if Hope/Helocyte and Pfizer.  Merck have completed phase 1 trials with adults with “no serious adverse events” which supports the move to phase 2, pregnant women, shortly.  Moderna and Helocyte are at initial stages of 1st phase and Pfizer unfortunately reported a failure and their study has been halted.

In terms of treatment, ganciclovir, which has been around for 30 years, is long overdue for something better and the main thrust of the presentations is that there is work going on, but with many challenges.
The parents forums are heartbreaking and interesting, seems very similar to the stories we have in the UK.

http://www.cmv2019.org/

     

Our Stories

Jamie-CMV
Hello, my son’s name is Jamie and he is 14 months old.  He was born with congenital CMV. Pregnancy wise, everything was normal, I had 5 scans, all fine... It was only 3 weeks... Read more
Siân was born on 11th March 1980, apparently normally after a normal pregnancy. She was small for birth-weight but this was not felt to be a problem – it runs in the family. The first few... Read more

Latest Events

Wednesday 02 October
Tuesday 31 December

Registered charity no: 1171773